refractory epilepsy - Robuta Search

https://www.globenewswire.com/de/news-release/2025/09/16/3150609/28124/en/Asia-Pacific-Refractory-Epilepsy-Treatment-Market-Research-2025-Market-to-Reach-2-48-Billion-by-2035-Opportunities-Fueled-by-a-Shift-from-Neo-Adjuvant-Approaches-Driven-by-Diagnost.html Asia-Pacific Refractory Epilepsy Treatment Market Research The Asia-Pacific refractory epilepsy treatment market is set to rise from $1.04 billion in 2024 to $2.48 billion by 2035, registering an 8.18% CAGR from... asia pacific refractory epilepsy treatment market research https://pubmed.ncbi.nlm.nih.gov/33714664/ Ketogenic diet for refractory epilepsy with MEHMO syndrome: Caution for acute necrotizing... The pathophysiology of glucose intolerance in MEHMO syndrome remains to be elucidated; however, recent studies have suggested that EIF2S3 gene variants could... ketogenic diet refractory epilepsy https://www.globenewswire.com/news-release/2025/09/16/3150609/28124/en/Asia-Pacific-Refractory-Epilepsy-Treatment-Market-Research-2025-Market-to-Reach-2-48-Billion-by-2035-Opportunities-Fueled-by-a-Shift-from-Neo-Adjuvant-Approaches-Driven-by-Diagnost.html Asia-Pacific Refractory Epilepsy Treatment Market Research The Asia-Pacific refractory epilepsy treatment market is set to rise from $1.04 billion in 2024 to $2.48 billion by 2035, registering an 8.18% CAGR from... asia pacific refractory epilepsy treatment market research https://cordis.europa.eu/project/id/753527/fr The ATP-P2X7R axis: a target for drug-refractory epilepsy | EpiPur | Projet | Fiche descriptive |... Current epilepsy therapies, based on mediating excitation or inhibition have no impact on disease progression and are ineffective in over 30% of patients,... https://pubmed.ncbi.nlm.nih.gov/36762646/ New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome NORSE and FIRES remain challenging conditions to diagnose and treat. Recent findings from clinical and basic research and new recommendations, reviewed in this... status epilepticus new onset refractory https://pubmed.ncbi.nlm.nih.gov/30185235/ Novel and de novo mutations in pediatric refractory epilepsy Pediatric refractory epilepsy is a broad phenotypic spectrum with great genetic heterogeneity. Next-generation sequencing (NGS) combined with Sanger sequencing... de novo novel mutations pediatric refractory https://www.cordis.europa.eu/project/id/753527/es The ATP-P2X7R axis: a target for drug-refractory epilepsy | EpiPur | Proyecto | Ficha informativa |... Current epilepsy therapies, based on mediating excitation or inhibition have no impact on disease progression and are ineffective in over 30% of patients,... https://www.cordis.europa.eu/project/id/753527/fr The ATP-P2X7R axis: a target for drug-refractory epilepsy | EpiPur | Projet | Fiche descriptive |... Current epilepsy therapies, based on mediating excitation or inhibition have no impact on disease progression and are ineffective in over 30% of patients,... https://cordis.europa.eu/project/id/190119321/es Oils4cure: finding an effective drug to alleviate Refractory Epilepsy, one of the most severe... OILS4CURE is a Spanish biotech company dedicated to the research, development, production and commercialisation of medicinal products based on full spectrum... one of the most https://cordis.europa.eu/project/id/753527 The ATP-P2X7R axis: a target for drug-refractory epilepsy | EpiPur | Project | Fact Sheet | H2020 |... Current epilepsy therapies, based on mediating excitation or inhibition have no impact on disease progression and are ineffective in over 30% of patients,...